Eptifibatide vs Abciximab as Adjunctive Therapy During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction
- Early Administration of Reteplase Plus Abciximab vs Abciximab Alone in Patients With Acute Myocardial Infarction Referred for Percutaneous Coronary Intervention: A Randomized Controlled Trial. Kastrati, Adnan; Mehilli, Julinda; Schlotterbeck, Klaus; Dotzer, Franz; Dirschinger, Josef; Schmitt, Claus; Nekolla, Stephan G.; Seyfarth, Melchior; Martinoff, Stefan; Markwardt, Christina; Clermont, Günther; Gerbig, Hans-Wilhelm; Leiss, Johannes; Schwaiger, Markus; Schömig, Albert // JAMA: Journal of the American Medical Association;2/25/2004, Vol. 291 Issue 8, p947
Context: The optimal pharmacological strategy for bridging the delay between admission and performance of percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (MI) is not known. Objective: To assess whether early administration of reteplase plus abciximab...
- Treatment delays in ST elevation mvocardial infarction. Terkelsen, Christian Julh; Lassen, Jens Flensted // BMJ: British Medical Journal (International Edition);2/23/2008, Vol. 336 Issue 7641, p401
The authors reflect on treatment delays in ST elevation myocardial infarction. They suggest that the delays can be reduced by prehospital diagnosis and the direct transfer to high volume catheterisation laboratories. They argue that setting up large volume treatment and intervention centers may...
- Fast, aggressive treatment for myocardial infarction urged. Mitka, Mike; Mitka, M // JAMA: Journal of the American Medical Association;12/20/2000, Vol. 284 Issue 23, p2985
Presents results from trials regarding myocardial infarction announced at the American Heart Association's annual scientific sessions in November 2000. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial and the use of atorvastatin in treatment; Treat Angina with...
- Reperfusion Therapy for Acute Myocardial Infarction: Which Strategy for Which Patient? Boersma, E.; Steyerberg, E.W.; van der Vlugt, M.J.; Simoons, M.L. // Drugs;Jul1998, Vol. 56 Issue 1, p31
Several modes of reperfusion therapy for evolving myocardial infarction (MI) have been developed, which differ in terms of effectiveness, complexity and costs. Reperfusion resources are often restricted by budgetary or logistical circumstances. To arrive at an equitable distribution of treatment...
- Acute Coronary Syndrome: A Concise Summary for the Non-cardiologist. McFeely, James E. // Critical Care Alert;May2009, Vol. 17 Issue 2, p14
The article offers information on the management of the acute coronary syndrome of ST-elevation myocardial infarction (STEMI).
- Treatment of Right Ventricular Infarction. Movahed, Assad // American Family Physician;10/15/1999, Vol. 60 Issue 6, p1640
Editorial. Discusses the treatment for right ventricular infarction. Occurrence of right ventricular infarction; Description of right ventricular infarction; Diagnosis of right ventricular infarction.
- Heart Attack Treatment. // HealthFacts;Feb2000, Vol. 25 Issue 2, p5
Provides information on the treatment for heart attack.
- A Multi-Country Health Economic Evaluation of Highly Concentrated N-3 Polyunsaturated Fatty Acids in Secondary Prevention after Myocardial Infarction. Lamotte, Mark; Annemans, Lieven; Kawalec, Pawel; Zoellner, York // PharmacoEconomics;2006, Vol. 24 Issue 8, p783
Background: Patients who survive an acute myocardial infarction (MI) are at an Abstract increased risk of subsequent major cardiovascular events and (often sudden) cardiac death. The use of highly concentrated and purified omega-3 polyunsaturated fatty acids (n-3 PUFAs), in addition to standard...
- Clinical profile of acute myocardial infarction patients in the absence of significant coronary artery disease. Pasupathy, S.; Tavella, R.; Arstall, M.; Chew, D.; Worthley, M.; Zeitz, C.; Beltrame, J. // Heart, Lung & Circulation;2015 Supplement 3, Vol. 24, pS142
No abstract available.